3 4 5

1 2

- 6 **Title:** Smoking, e-cigarettes and the effect on respiratory symptoms among a population sample 7 of youth: retrospective study.
- 8
- 9 Authors: Chaiton M PhD<sup>1,2</sup>, Pienkowski M BSc<sup>1</sup>, Musani I MPH<sup>1</sup>, Bondy SJ PhD<sup>1</sup>, Cohen JE
- 10 PhD<sup>3</sup> Dubray J MSc<sup>1</sup>, Eissenberg TE PhD<sup>4</sup>, Kaufman P PhD<sup>1</sup>, Stanbrook MB MD PhD<sup>5</sup>,
- 11 Schwartz R PhD<sup>1,2</sup>.
- <sup>1</sup>Dalla Lana School of Public Health, University of Toronto, Canada; <sup>2</sup>Centre for Addiction and
- 13 Mental Health, Toronto, Canada; <sup>3</sup>Institute for Global Tobacco Control, Department of Health,
- 14 Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA;
- <sup>4</sup>Department of Psychology, Virginia Commonwealth University; <sup>5</sup>Division of Respirology,
- 16 Department of Medicine, University of Toronto, Canada.
- 17

### 18 **Corresponding Author**:

- 19 Michael Chaiton
- 20 Ontario Tobacco Research Unit
- 21 Centre for Addiction and Mental Health
- 22 155 College St.
- 23 Toronto, Ontario, M5T 3M7
- 24 Tel: 416-978-7096
- 25 Fax: 416-595-6068
- 26 Email: michael.chaiton@camh.ca
- 27
- 28 Word count: 2659
- 29 **Contributors**
- 30 Guarantor: Michael Chaiton takes responsibility for (is the guarantor of) the content of the
- 31 manuscript, including the data and analysis.
- 32 Financial disclosure Dr. Eissenberg is a paid consultant in litigation against the tobacco industry
- 33 and also the electronic cigarette industry and is named on one patent for a device that measures
- 34 the puffing behavior of electronic cigarette users and on another patent for a smartphone app that
- 35 determines electronic cigarette device and liquid characteristics. Other authors have no
- 36 disclosures to report.
- 37 **Conflict of interests**/The CSTP is supported by grant number U54DA036105 from the National
- 38 Institute on Drug Abuse of the National Institutes of Health and the Center for Tobacco Products
- 39 of the U.S. Food and Drug Administration. The content of this message is solely the
- 40 responsibility of the author and does not necessarily represent the views of the NIH or the FDA
- 41 The cohort study was funded by CIHR. The funding sources had no role in the study design,
- 42 collection, analysis, and interpretation of data, writing the report and the decision to submit the
- 43 report for publication.
- 44 **Data sharing:** De-identified participant data can be made available upon request to researchers
- 45 with permission from an academic ethics review board.

#### 46 Abstract

- 47 Introduction: E-cigarettes have been steadily increasing in popularity, both as cessation
- 48 methods for smoking and for recreational and social reasons. This increase in vaping may pose
- 49 cardiovascular and respiratory risks. We aimed to assess respiratory symptoms in youth users of
- 50 e-cigarettes and cigarettes.
- 51 **Methods:** A cross-sectional survey design was utilized to assess Canadian youth aged 16-25
- 52 years old. Participants were recruited from the Ontario Tobacco Research Unit Youth and Young
- Adult Research Registration Panel November 2020 to March 2021. A total of 3,082 subjects
- 54 completed the baseline survey. Of these, 2660 individuals who did not have asthma were
- 55 included in the analysis. The exposure of interest was vaping dose, pack equivalent years,
- 56 equivalent to cigarette pack years incorporating number of puffs per day, number of days vaped
- 57 per month, and number of years vaped. Respiratory symptoms were measured using the five-
- 58 item Canadian Lung Health Test. Poisson regression analyses were performed while adjusting
- 59 for demographic confounders, stratified by smoking status. A non-stratified model tested the
- 60 interaction of status and vaping dose and the effect of vaping device used was assessed among
- 61 ever vapers. Analyses controlled for demographic characteristics, use of cannabis and alcohol,
- 62 and survey date.
- 63 **Results:** Each additional puff year increased the rate ratio of respiratory symptoms by a factor of

64 11.36 (95%CI: 4.61-28.00; p<0.001) for never smokers, but among current daily smokers higher

65 pack equivalent years were not associated with more respiratory symptoms (0.83; 95% CI: 0.23.,

- 66 3.11). Among current vapers, those using pod-style devices were more likely to have more
- 67 respiratory symptoms (1.25; 95% CI: 1.08, 1.45) after adjusting for dose.
- 68 **Conclusions** Vaping is associated with an increased risk of reporting respiratory symptoms
- among never smoking youth and non-daily ever cigarette smokers. Use of e-cigarettes among
- 70 non-smokers should be discouraged.
- 71
- 72 Funding Canadian Institutes of Health Research
- 73
- 74

#### 75 Introduction

Cigarette smoking has long been known to be associated with poor respiratory health outcomes,
including lung cancer, chronic obstructive pulmonary disease (COPD), and severe asthma.<sup>1</sup> In
the past several decades, the prevalence of cigarette smoking has decreased drastically across
North America. Even so, it remains prevalent with an estimated 14.8% of Canadians smoking
cigarettes in 2019, which is slightly higher than rates of 14.1% in the United Kingdom and
14.0% in the United States.<sup>2,3,4</sup>

82 While the use of cigarettes has become less common, electronic cigarettes (e-cigarettes) have 83 quickly gained global popularity as both smoking cessation aids as well as recreational nicotine 84 delivery devices.<sup>5</sup> This rise in use has been especially prominent amongst youth, with several 85 studies observing large increases in the prevalence of youth e-cigarette use in both the United 86 States and Canada within the past decade, with 15% of youth in Canada aged 15 to 19 reporting past 30-day use of e-cigarettes in 2019, compared to only 6% in 2017.<sup>6,7,8</sup> Despite being initially 87 88 introduced as a supposedly safer alternative to cigarettes, e-cigarettes have been found to be 89 associated with some health-related harms similar to cigarettes.<sup>9,10</sup> Further, the use of e-cigarettes has been associated with additional harms unique to the electronic devices.<sup>10</sup> Literature 90 91 surrounding the health impacts of e-cigarette use is still evolving, but existing research has 92 identified both short- and long-term respiratory harms due to e-cigarette use.<sup>11</sup> However, existing 93 research primarily includes adult samples, limiting generalizability to youth populations, which 94 differ biologically, psychologically, and sociologically. Further research is thus necessary to 95 assess the effect of vaping frequency on risk of respiratory symptoms, especially among youth 96 who are at highest risk of vaping initiation. Additionally, the association between vaping device 97 type/e-cigarette liquid flavour and respiratory symptoms must be assessed as different devices

provide varying doses of vapor per puff, which may impact risk of respiratory symptoms among
users of certain device types, even with a lower vaping frequency.

100 In addition, many individuals engage in dual use of cigarettes and e-cigarettes.<sup>12,13</sup> Motivations

101 for dual use vary, with research suggesting that individuals who initiate the use of e-cigarettes

102 with the goal of smoking cessation are more likely to engage in dual use than to engage in e-

103 cigarette use alone.<sup>12</sup> This may be the case because smokers who use e-cigarettes as smoking

104 cessation aids may not fully transition from smoking to vaping, despite often beginning with the

105 intention to quit smoking entirely.<sup>12</sup>

107

108

106 Research surrounding the health impacts of the dual use of cigarettes and e-cigarettes remains

mitigated health-related harms due to the overall decrease in the use of cigarettes.<sup>12,13</sup> Other

limited. Results from existing studies have been mixed, with some finding that dual use leads to

109 research has found that the potential mitigation of health-related harms as a result of switching

110 from cigarettes to e-cigarettes are negated in those who continue to smoke cigarettes alongside

111 using e-cigarettes. This may be observed as no difference in health-related harms between dual

112 users and single product users or increased harms among dual users. Notably, most of these

113 studies focus on the health-related impacts of either smoking or vaping, but not both.<sup>14-18</sup> Finally,

114 much research remains inconclusive surrounding the harms associated with the dual use of

115 cigarettes and e-cigarettes, as well as with regards to how these impacts differ between

116 individuals who are solely users of either cigarettes or e-cigarettes.<sup>12</sup>

The current analysis sought to use survey data to understand better the association between ecigarette use and self-reported respiratory symptoms among youth, along with the association between self-reported respiratory symptoms and e-cig dose (number of puffs per month), vaping device, e-cigarette liquid flavour, and years vaped. In doing so, we seek to add to a growing body

121 of research regarding the extent of harms related to the use of e-cigarettes. Additionally, the 122 study aims to assess the interaction associated with the dual use of cigarettes and e-cigarettes on 123 respiratory symptoms. Based on current research on both vaping and smoking cigarettes, we 124 hypothesized that individuals who smoked cigarettes regularly and those who vaped regularly 125 would report more respiratory symptoms compared to non-smokers and non-vapers. We further 126 hypothesized that dual use of cigarettes and e-cigarettes would be associated with more 127 respiratory symptoms compared to vaping alone, but lower compared to cigarette smoking alone, 128 due to satiation of cravings that would decrease cigarettes smoked daily. However, this 129 assumption of decreased cigarette intake may be incorrect, as some studies reported lower levels 130 of smoking in dual users, while others reported no notable change in number of cigarettes 131 smoked, though fewer respiratory symptoms were still observed.<sup>18</sup> To further this understanding, 132 we also considered potential confounding factors in the relationship between smoking and 133 respiratory health, including age, sex, education level, and other substance use. 134

#### 135 Methods

#### 136 Data Source

Participants were recruited from the Ontario Tobacco Research Unit Youth and Young Adult
Research Registration Panel November 2020 to March 2021 (Pienkowski, 2021). Panel
recruitment was completed via social media advertisements from August 2020 to February 2021.
Panel participants completed a recruitment survey and provided information for future contact.
From the panel, adolescents and young adults aged 16-25 living in Canada were eligible for the
survey. Targeted recruitment by email was used to balance the survey respondents for vaping

143 status (never, ever (at least one puff), past 30 days), smoking status (never, ever, past 30 days)

and age (16-18, 19-25). Participation rate was 60%. Younger females, those with higher
education, and those who had never used e-cigarettes or cigarettes were more likely to
participate. There were 3082 youth who completed the baseline survey including 396 individuals
reporting a diagnosis of asthma. The University of Toronto Research Ethics Board provided
ethics approval.

149

#### 150 Measures

151 The primary exposure variables was pack-equivalent years. This value was calculated

152 equivalents to the pack-years calculation for cigarettes. The number of reported puffs per day on

153 days vaped (divided by 10, the standard number of puffs in a cigarette) was multiplied by the

154 number of days vaped per month (divided by 30 to provide an average daily use). This value was

155 then divided by 20 to convert to packs (20 cigarettes per pack) and then multiplied by the

156 number of years of vaping report (current age-age at first vape).

157 The outcome variable was the self-reported occurrence of adverse respiratory symptoms. Data on

158 five respiratory symptoms were collected, with survey respondents identifying any symptoms

they experienced in the past four months (yes/no). The five symptoms were coughing regularly,

160 coughing up phlegm regularly, feeling out of breath from even simple chores, wheezing when

161 exerting oneself (e.g., through exercise or going up the stairs), and getting many colds

162 (specifically those that take longer to recover). The five questions were combined to form an

163 overall respiratory symptoms variable, the Canadian Lung Health Test. This measure was

164 originally validated for use in screening for COPD but comprises a set of questions routinely

165 used by clinicians to evaluate patients for respiratory disorders.<sup>19</sup> The maximum number of

respiratory symptoms that could be selected by a respondent was five and the minimum numberof symptoms was zero.

Cigarette status was self reported and categorized into (never smoked a cigarette, smoked a cigarette but not a current daily smoker, and daily smoker). Participants also reported number of cigarettes smoked per day, and whether or not they were past month users of alcohol and cannabis. Participants were asked what vaping device they had last used, and how long they had been vaping at the time of survey completion. Data on demographic characteristics were also collected (sex, age, education, parental status, marital status, province of residence, and race). Participants also reported whether or not they had received a diagnosis of asthma.

#### 176 Statistical Analysis

This analysis assessed the effect of e-cigarette use and frequency on the rate ratios of respiratory symptoms, assessed via a Poisson regression model. The interaction between e-cigarette puffs per day and number of cigarettes smoked per day on respiratory symptoms was also assessed. All other covariates in the model were chosen based on past research. Covariates were included in the analysis if they were deemed to be conceptually relevant as confounders. Covariates were respondent age, sex, race, education level, race, province and history of substance-use other than cigarettes or e-cigarettes.

An additional Poisson regression analysis was conducted which assessed effects of self-reported vaping device type, vaping flavour, and number of years since starting vaping on respiratory symptoms among current e-cigarette users. Analyses were performed using Stata/IC 16.1.

- 187
- 188

#### 189 **Results**

190 Descriptive statistics were calculated for all variables included in the Poisson regression model

and outlined in Table 1. The average age of participants included in this analysis was 19.6 years

192 (SD=2.7), ranging from 16 to 25 years. The majority of respondents were white (n=2270,

193 73.7%) and 80.6% were female (n=2456). 396 individuals reporting a diagnosis of asthma.

194 Descriptive statistics for all analyzed variables can be seen in Table 1.

195

196 Half of respondents reported either never vaping or not currently vaping at all (n=1554, 50.4%),

197 10.5% reported less than monthly vaping (n=323), 5.4% reported vaping monthly (n=165), 5.8%

198 vaped weekly (n=178), and 28.0% reported vaping daily (n=862). The average number of

199 cigarettes smoked per day among ever-smokers in the sample was 4.4 (SD=7.2), while the daily

average among exclusive current daily smokers was 9.8 (SD=11.8) and the daily average among

201 current daily dual users was 5.7 (SD=5.9) cigarettes per day. Never smokers who vaped had

202 lower numbers of puffs per day, number of days vaped per month, and number of years vaped

203 than ever smokers and daily smokers (Table 2).

204

Table 3 outlines the percentage distribution of respiratory symptoms by smoking and vaping status. Half of respondents reported zero respiratory symptoms (51.5%). Of never-users, nondaily and daily e-cigarette users, the highest proportion of respondents reported zero symptoms (65.8%, 56.8%, and 34.2%, respectively), compared to the highest proportion of daily smokers who reported experiencing one respiratory symptom (23.2%), and the highest proportion of dualusers who reported experiencing two respiratory symptoms (25.0%). While for three of the five symptoms the majority of participants did not report experiencing the symptom, regardless of

212	smoking or vaping status, the majority of daily smokers, regardless of vaping status, did report
213	coughing regularly in the last four months (65.6% of daily smokers, non-vapers; 57.1% of daily
214	smokers, daily vapers), and the majority of daily smokers, non-vapers reported coughing up
215	phlegm regularly (52.2%). Additionally, daily smokers, daily vapers, and daily dual-users were
216	all more likely to report experiencing any of the five symptoms compared to non-daily or never-
217	users of either cigarettes or e-cigarettes. Daily smokers were also more likely to report
218	experiencing any symptoms compared to daily vapers. Dual users had lower rates of reporting of
219	all symptoms compared to daily smoking alone, especially when looking at wheezing (35.8% of
220	dual-users, compared to 46.1% of daily smokers) (p<0.05 for cold frequency and duration,
221	p<0.001 for all other respiratory symptoms and total number of symptoms).
222	
223	Each additional puff year increased the rate ratio of respiratory symptoms by a factor of 11.36
224	(95%CI: 4.61-28.00; p<0.001) for never smokers and ever smokers (2.79; 95% CI: 1.69, 4.61),
225	but among current daily smokers higher pack equivalent years were not associated with more
226	respiratory symptoms (0.83; 95% CI: 0.23., 3.11) (Table 4). Test of interactions were
227	statistically significant (p<0.001) (See supplemental files).
228	
229	Figure 1 depicts the modelled relationship between pack equivalent years and number of
230	respiratory symptoms, by cigarette smoking status. Never smokers with no vaping history have
231	fewer respiratory symptoms than those who have smoked with average number of symptoms of
232	respiratory symptoms approaches the level seen in daily smokers after 0.5 puff year. Daily

smokers do not demonstrate increasing symptoms with greater pack equivalent years.

234

Among current vapers, those using pod-style devices were more likely to have more respiratory
symptoms (1.25; 95% CI: 1.08, 1.45) after adjusting for dose (See supplemental files).

237

#### 238 Discussion

239 Our analysis found that use of e-cigarettes was associated with increased rate of respiratory

symptoms, and that the greater the frequency of vaping the higher the number of symptoms.

241

242 Unsurprisingly, higher amounts of cigarette smoking were also strongly associated with more 243 respiratory symptoms. This population of youth and young adults reflects a lighter smoking 244 sample than would be found among all adults. Exclusive daily smokers reported smoking an 245 average of 9.8 cigarettes per day, while dual users reported smoking an average of 5.7 cigarettes 246 per day, which is notably lower than previous research that showed an average daily cigarette 247 consumption among Canadian daily smokers of 13.7 in 2017.<sup>20</sup> Despite this level of smoking, 248 elevated respiratory symptoms were higher in smokers than non-smokers indicating the 249 dangerousness of cigarettes. Similarly, this population of youth and young adults have limited 250 number of years of experience vaping, but despite this, increased frequency and length of time 251 vaping was associated with increased numbers of respiratory symptoms that can, with sufficient 252 dose, approach the short term respiratory harms associated with smoking cigarettes.

253

With regards to dual use, however, we observed that those individuals who vaped daily and smoked cigarettes daily did not demonstrate additional risk from vaping. That is, dual users reported notably high levels of respiratory symptoms compared to non-users of both cigarettes and e-cigarettes, though an increase in e-cigarette puffs resulted in a marginal decrease in rate of

respiratory symptoms. These results are congruent with existing studies that reported health
benefits of dual use compared to exclusive cigarette smoking.<sup>12,13,15,17</sup> However, due to the high
baseline of respiratory symptoms among cigarette smokers, it is difficult to ascertain the true
benefit of dual-use without longitudinally monitoring changes in smoking behaviours of
exclusive smokers that become dual users, to determine the mechanism behind this decrease in
symptoms.

264

This study also builds on these results via the inclusion of a vaping-only group, as well as via the inclusion of youth participants, which allows for more specified results and interpretations.

267 Though the specification of age may limit generalizability to the overall population, it also

allows for increased accuracy and reliability in constructing prevention and treatment plans for

269 youth. Additional studies that monitor exact number of cigarettes smoked and e-cigarette puffs

among single users versus dual users are needed to confirm this.

Those who vaped pod like devices reported higher levels of symptoms after controlling for puff year. This finding is consistent with previous results wherein adolescents reported experiencing worse respiratory symptoms when using specific vape brands and products, particularly JUUL, a pod device with a nicotine salt liquid.<sup>21</sup> As was expected, subjects with a longer history of vaping experienced more respiratory symptoms than newer vapers, as they have likely inhaled a larger number of total puffs.

277

#### 278 Limitations

While this analysis provided insight into the association between the dual use of vaping and smoking on respiratory health symptoms, there are limitations that should be noted. First, there

281 are substantial limitations to the generalizability of this survey due to the purposive online 282 sampling. The high participation of females suggests that the results are more robust for young 283 females. While the anonymous, online nature of the survey may encourage honesty, there is also 284 a risk of recall bias, as participants may incorrectly recall their use behaviours or respiratory 285 symptoms, either unintentionally or intentionally, especially if they are advocates for smoking or 286 vaping. Additional studies that include physical assessments of subjects' respiratory health and 287 biomarkers of smoking/vaping are necessary to achieve more accurate and reliable results. 288 The cross-sectional nature of these data also presents some limitations with regards to the 289 conclusions that can be drawn from our analysis. Because survey respondents were asked about 290 their use of cigarettes and e-cigarettes simultaneously and retrospectively, it is unclear how 291 patterns of use changed over the lifecourse and how these reported symptoms may or may not 292 lead to medical diagnosis of disease long term.

293

#### 294 Conclusion

295 This study documented a potential correlation between vaping and an increase in respiratory

symptoms. A secondary finding was an interaction between dual use of cigarettes and e-

297 cigarettes and a decreased risk of respiratory symptoms compared to cigarette smoking alone,

- which exhibited a higher baseline of symptoms. Further longitudinal research using physical
- 299 health assessments and biomarkers is necessary to explore this association further.

300

#### 301 Acknowledgements

Dr. Eissenberg is a paid consultant in litigation against the tobacco industry and also the
 electronic cigarette industry and is named on one patent for a device that measures the puffing
 behavior of electronic cigarette users and on another patent for a smartphone app that determines
 electronic cigarette device and liquid characteristics. Other authors have no disclosures to report.
 The CSTP is supported by grant number U54DA036105 from the National Institute on Drug
 Abuse of the National Institutes of Health and the Center for Tobacco Products of the U.S. Food

- 308 and Drug Administration. The content of this message is solely the responsibility of the author
- 309 and does not necessarily represent the views of the NIH or the FDA The cohort study was funded
- 310 by CIHR. The funding sources had no role in the study design, collection, analysis, and
- 311 interpretation of data, writing the report and the decision to submit the report for publication.

#### References

- 1 Centres for Disease Control and Prevention. Health effects of cigarette smoking. 2020. Available from: https://www.cdc.gov/tobacco/data\_statistics/fact\_sheets/health\_effects/effects\_cig\_smoking/index.htm
- 2 Statistics Canada. *Table 13-10-0096-10 Smokers, by age group*. Retrieved from https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310009610
- 3 Office for National Statistics. Adult smoking habits in the UK: 2019. 2020. Accessed July 2021.
- 4 Cornelius ME, Wang TW, Jamal A, Loretan CG, Neff LJ. Tobacco product use among adults United States, 2019. MMWR Morb Mortal Wkly Rep 2020;69:1736–1742.
- 5 Fadus MC, Smith TT, Squeglia LM. The rise of e-cigarettes, pod mod devices, and JUUL among youth: factors influencing use, health implications, and downstream effects. *Drug Alcohol Depend* 2019;201:85– 93.
- 6 Hammond D, Reid JL, Rynard VL, et al. Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: repeat national cross sectional surveys. *BMJ* 2019;**20**:365.
- 7 Government of Canada. Canadian Tobacco and Nicotine Survey (CTNS): Summary of Results for 2019. Accessed February 16, 2021.
- 8 Government of Canada. Canadian Tobacco Alcohol and Drugs (CTADS): Summary of Results for 2017. Accessed February 15, 2021.
- 9 Franck C, Budlovsky T, Windle SB, Filion KB, Eisenberg MJ. Electronic cigarettes in North America: history, use, and implications for smoking cessation. *Circulation* 2014;**129(19)**:1945–52.
- 10 Krishnasamy VP, Hallowell BD, Ko JY, et al. Update: characteristics of a nationwide outbreak of ecigarette, or vaping, product use-associated lung injury—United States, August 2019–January 2020. MMWR Morb Mortal Wkly Rep 2020;69(3):90.
- 11 Miyashita L, Foley G. E-cigarettes and respiratory health: the latest evidence. *J Physiol* 2020;**598(22)**:5027–38.
- 12 Robertson L, Hoek J, Blank ML, Richards R, Ling P, Popova L. Dual use of electronic nicotine delivery systems (ENDS) and smoked tobacco: a qualitative analysis. *Tob control* 2019;**28(1)**:13–9.
- 13 Owusu D, Huang J, Weaver SR, et al. Patterns and trends of dual use of e-cigarettes and cigarettes among US adults, 2015–2018. *Prev Med Rep* 2019;**16**:101009.
- 14 Osei AD, Mirbolouk M, Orimoloye OA, et al. Association between e-cigarette use and cardiovascular disease among never and current combustible-cigarette smokers. *Am J Med* 2019;**132(8)**:949–54.
- 15 Parekh T, Pemmasani S, Desai R. Risk of stroke with E-cigarette and combustible cigarette use in young adults. *Am J Prev Med* 2020;**58(3)**:446–52.
- 16 Wang JB, Olgin JE, Nah G, et al. Cigarette and e-cigarette dual use and risk of cardiopulmonary symptoms in the Health eHeart Study. *PloS One* 2018;**13**(7):e0198681.
- 17 Abafalvi L, Pénzes M, Urbán R, Foley KL, Kaán R, Kispélyi B, Hermann P. Perceived health effects of vaping among Hungarian adult e-cigarette-only and dual users: a cross-sectional internet survey. BMC Public Health 2019;19(1):1–0.
- 18 Cobb CO, Foulds J, Yen MH, et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial. *Lancet Respir Med* 2021; 1-11.
- 19 Robitaille C, Dajczman E, Hirsch AM, et al. Implementation of a targeted screening program to detect airflow obstruction suggestive of chronic obstructive pulmonary disease within a presurgical screening clinic. *Can Respir J*. 2015;**22(4)**:209-214.
- 20 Canadian Tobacco Use Monitoring Survey, 1999-2012; Canadian Tobacco, Alcohol and Drugs Survey, 2013, 2015, 2017. Accessed July 2021.
- 21 Kechter A, Schiff SJ, Simpson KA, et al. Young adult perspectives on their respiratory health symptoms since vaping, *Subst Abus* 2020;1–13.
- 22 Canadian Tobacco, Alcohol and Drugs Survey (CTADS), 2017

#### Tables

#### Table 1. Demographics for all variables included in the multivariable linear regression model

	Total	Never-use of both smoking and vaping	Non-daily ever-use of either smoking or vaning	Daily vaping, non- daily/never smoking	Daily smoking, non- daily/never yaning	Daily vaping, daily smoking
	N=3,082	N=825	N=1,303	N=820	N=92	N=42
Age	19.6 (2.7)	18.8 (2.6)	20.1 (2.8)	19.6 (2.5)	21.6 (2.6)	19.6 (2.5)
16-19	1,689 (54.8%)	561 (68.0%)	634 (48.7%)	448 (54.6%)	22 (23.9%)	24 (57.1%)
20-25	1,393 (45.2%)	264 (32.0%)	669 (51.3%)	372 (45.4%)	70 (76.1%)	18 (42.9%)
Sex						
Male	593 (19.4%)	116 (14.2%)	219 (17.0%)	227 (28.0%)	17 (18.9%)	14 (33.3%)
Female	2,456 (80.6%)	701 (85.8%)	1,071 (83.0%)	583 (72.0%)	73 (81.1%)	28 (66.7%)
Race						
White	2,270 (73.7%)	494 (59.9%)	983 (75.4%)	682 (83.2%)	78 (84.8%)	33 (78.6%)
Black	62 (2.0%)	22 (2.7%)	32 (2.5%)	8 (1.0%)	0 (0.0%)	0 (0.0%)
Chinese	201 (6.5%)	109 (13.2%)	72 (5.5%)	20 (2.4%)	0 (0.0%)	0 (0.0%)
Filipino	43 (1.4%)	18 (2.2%)	15 (1.2%)	10 (1.2%)	0 (0.0%)	0 (0.0%)
Indigenous	63 (2.0%)	5 (0.6%)	26 (2.0%)	22 (2.7%)	6 (6.5%)	4 (9.5%)
Japanese	4 (0.1%)	0 (0.0%)	3 (0.2%)	1 (0.1%)	0 (0.0%)	0 (0.0%)
Korean	19 (0.6%)	7 (0.8%)	7 (0.5%)	4 (0.5%)	1 (1.1%)	0 (0.0%)
Latin-Central-South American	55 (1.8%)	12 (1.5%)	29 (2.2%)	11 (1.3%)	2 (2.2%)	1 (2.4%)
Southeast Asian	38 (1.2%)	21 (2.5%)	12 (0.9%)	5 (0.6%)	0 (0.0%)	0 (0.0%)
South Asian	182 (5.9%)	99 (12.0%)	65 (5.0%)	16 (2.0%)	2 (2.2%)	0 (0.0%)
West Asian or Arab	56 (1.8%)	14 (1.7%)	30 (2.3%)	9 (1.1%)	1 (1.1%)	2 (4.8%)
Other	89 (2.9%)	24 (2.9%)	29 (2.2%)	32 (3.9%)	2 (2.2%)	2 (4.8%)
Province						
Ontario	1,531 (49.7%)	478 (57.9%)	664 (51.0%)	322 (39.3%)	49 (53.3%)	18 (42.9%)
Alberta	496 (16.1%)	104 (12.6%)	203 (15.6%)	168 (20.5%)	15 (16.3%)	6 (14.3%)
British Columbia	483 (15.7%)	111 (13.5%)	210 (16.1%)	144 (17.6%)	10 (10.9%)	8 (19.0%)
Manitoba	116 (3.8%)	25 (3.0%)	52 (4.0%)	32 (3.9%)	6 (6.5%)	1 (2.4%)
New Brunswick	53 (1.7%)	15 (1.8%)	14 (1.1%)	22 (2.7%)	2 (2.2%)	0 (0.0%)
Newfoundland and Labrador	40 (1.3%)	6 (0.7%)	16 (1.2%)	17 (2.1%)	0 (0.0%)	1 (2.4%)
Nova Scotia	102 (3.3%)	27 (3.3%)	47 (3.6%)	24 (2.9%)	2 (2.2%)	2 (4.8%)
Prince Edward Island	16 (0.5%)	2 (0.2%)	5 (0.4%)	9 (1.1%)	0 (0.0%)	0 (0.0%)
Quebec	129 (4.2%)	28 (3.4%)	59 (4.5%)	34 (4.1%)	3 (3.3%)	5 (11.9%)
Saskatchewan	113 (3.7%)	27 (3.3%)	33 (2.5%)	47 (5.7%)	5 (5.4%)	1 (2.4%)
Northwest Territories	2 (0.1%)	1 (0.1%)	0 (0.0%)	1 (0.1%)	0 (0.0%)	0 (0.0%)
Yukon	1 (0.0%)	1 (0.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Highest education level						
Some elementary or high school	764 (24.8%)	286 (34.7%)	261 (20.0%)	185 (22.6%)	21 (22.8%)	11 (26.2%)
Completed High school	1,489 (48.3%)	356 (43.2%)	604 (46.4%)	469 (57.2%)	40 (43.5%)	20 (47.6%)
College diploma	268 (8.7%)	33 (4.0%)	133 (10.2%)	79 (9.6%)	18 (19.6%)	5 (11.9%)
University or post graduate degree	561 (18.2%)	150 (18.2%)	305 (23.4%)	87 (10.6%)	13 (14.1%)	6 (14.3%)

Marital status						
Single	2,577 (83.6%)	768 (93.1%)	1,058 (81.2%)	658 (80.2%)	63 (68.5%)	30 (71.4%)
Married or living with a partner	501 (16.3%)	55 (6.7%)	244 (18.7%)	162 (19.8%)	28 (30.4%)	12 (28.6%)
Divorced/Separated/Widowed	4 (0.1%)	2 (0.2%)	1 (0.1%)	0 (0.0%)	1 (1.1%)	0 (0.0%)
Parental status						
Yes	60 (1.9%)	4 (0.5%)	28 (2.1%)	20 (2.4%)	8 (8.7%)	0 (0.0%)
No	3,022 (98.1%)	821 (99.5%)	1,275 (97.9%)	800 (97.6%)	84 (91.3%)	42 (100.0%)
Vaping device type (last used)						
Modifiable/tubular device	331 (15.9%)		180 (15.6%)	122 (15.2%)	23 (25.8%)	6 (14.3%)
Pod system	1,426 (68.3%)		753 (65.1%)	599 (74.9%)	47 (52.8%)	27 (64.3%)
Other <sup>1</sup>	331 (15.9%)		224 (19.4%)	79 (9.9%)	19 (21.3%)	9 (21.4%)
E-liquid flavour (last used)						
Fruit/Candy/Dessert/Food	1,351 (64.0%)		737 (62.5%)	531 (66.5%)	54 (60.7%)	29 (69.0%)
Beverage	35 (1.7%)		23 (1.9%)	9 (1.1%)	1 (1.1%)	2 (4.8%)
Mint/Menthol	387 (18.3%)		175 (14.8%)	192 (24.0%)	13 (14.6%)	7 (16.7%)
Tobacco	59 (2.8%)		23 (1.9%)	25 (3.1%)	8 (9.0%)	3 (7.1%)
Other	82 (3.9%)		42 (3.6%)	34 (4.3%)	5 (5.6%)	1 (2.4%)
I don't know	196 (9.3%)		180 (15.3%)	8 (1.0%)	8 (9.0%)	0 (0.0%)
How often do you currently vape?						
Daily or almost daily	862 (28.0%)	0 (0.0%)	0 (0.0%)	820 (100.0%)	0 (0.0%)	42 (100.0%)
Less than daily, but at least once a week	178 (5.8%)	0 (0.0%)	154 (11.8%)	0 (0.0%)	24 (26.1%)	0 (0.0%)
Less than weekly, but at least once a month	165 (5.4%)	0 (0.0%)	150 (11.5%)	0 (0.0%)	15 (16.3%)	0 (0.0%)
Less than monthly	323 (10.5%)	0 (0.0%)	302 (23.2%)	0 (0.0%)	21 (22.8%)	0 (0.0%)
Not at all	622 (20.2%)	0 (0.0%)	593 (45.5%)	0 (0.0%)	29 (31.5%)	0 (0.0%)
I have never vaped	932 (30.2%)	825 (100.0%)	104 (8.0%)	0 (0.0%)	3 (3.3%)	0 (0.0%)
Cigarettes smoked daily	4.4 (7.2)		1.9 (3.0)	3.2 (4.7)	9.8 (11.8)	5.7 (5.9)
Daily alcohol/cannabis use	878 (28.5%)	30 (3.6%)	348 (26.7%)	420 (51.2%)	51 (55.4%)	29 (69.0%)
Asthma diagnosis	396 (12.8%)	107 (13.0%)	154 (11.8%)	106 (12.9%)	19 (20.7%)	10 (23.8%)

<sup>1</sup>Other devices: disposable or rechargeable cigarette-like vaping devices, pen-like devices, and other.

## Table 2. Mean number of puffs per day vaped, number of days per month vaped, number of years vaped, by smoking status (never, ever, and daily) among ever vapers (n=2150)

	Never Smo (n=840	okers I)	Ever Smokers (excep (n=1118)	Daily Smoker (n=192)		
	Mean	SD	Mean	SD	Mean	SD
Number of puffs per day	3.2	0.2	5.9	0.2	7.8	0.7
Number of days vaped	6.4	0.4	12.6	0.4	13.6	1
Number of years vaped	1.7	0.1	2.4	0.1	2.2	0.2

## Table 3: Descriptive statistics of percentage of participants with respiratory symptoms by smoking and vaping status

	Total	Never-use of both smoking and vaping	Non-daily ever-use of either smoking or vaping	Daily vaping, non- daily/never smoking	Daily smoking, non- daily/never vaping	Daily vaping, daily smoking	p-value	
	N=3,082	N=825	N=1,303	N=820	N=92	N=42		
Number of respiratory symptoms N= 2,973								
0	1,531 (51.5%)	534 (65.8%)	712 (56.8%)	266 (34.2%)	12 (13.3%)	7 (17.5%)		
1	683 (23.0%)	168 (20.7%)	277 (22.1%)	209 (26.9%)	21 (23.3%)	8 (20.0%)		
2	425 (14.3%)	76 (9.4%)	166 (13.2%)	156 (20.1%)	17 (18.9%)	10 (25.0%)		
3	186 (6.3%)	21 (2.6%)	66 (5.3%)	77 (9.9%)	17 (18.9%)	5 (12.5%)		
4	111 (3.7%)	11 (1.4%)	23 (1.8%)	53 (6.8%)	16 (17.8%)	8 (20.0%)		
5	37 (1.2%)	1 (0.1%)	10 (0.8%)	17 (2.2%)	7 (7.8%)	2 (5.0%)		
Over the past	4 months, did y	ou cough regula	arly? N=2,999	1		1	< 0.001	
Yes	686 (22.9%)	81 (9.9%)	207 (16.4%)	315 (40.1%)	59 (65.6%)	24 (57.1%)		
Over the past	4 months, did y	ou cough up ph	legm regularly?	N=2,996			< 0.001	
Yes	509 (17.0%)	67 (8.2%)	170 (13.4%)	206 (26.3%)	47 (52.2%)	19 (45.2%)		
Over the past 4 months, did even simple chores make you short of breath? N=2,992							< 0.001	
Yes	629 (21.0%)	94 (11.5%)	231 (18.3%)	242 (30.9%)	41 (45.6%)	21 (51.2%)		
Over the past	4 months, did y	ou wheeze when	n you exert your	self? N=2,995	1	1	< 0.001	
Yes	673 (22.5%)	135 (16.5%)	254 (20.1%)	223 (28.4%)	43 (47.8%)	18 (43.9%)		
Over the past 4 months, did you get many colds and do your colds usually last longer than your friends' colds? N=2,999						<0.05		
Yes	247 (8.2%)	61 (7.5%)	97 (7.6%)	70 (8.9%)	15 (16.7%)	4 (9.8%)		

Table 4. Poisson regression summary table of rate ratios for effects of vaping and smoking frequencies on respiratory symptoms stratified by smoking status)

	Non Smokers	Ever Smokers	Daily Smokers
Respiratory symptoms			
Pack equivalent	11.36***	2.79***	0.84
years	[4.61,28.00]	[1.69,4.61]	[0.23,3.11]
Ν	1445	1059	156

<sup>2</sup>Exponentiated coefficients adjusted for respondent age, sex, education, marital status, parental status, registration date, other daily drug use, province, and race, those who reported a diagnosis of asthma are excluded. Full tables with covariates available in Supplementary Materials (Supplementary Table 1). \* p<0.05, \*\* p<0.01, \*\*\* p<0.001

Figure 1. Modelled number of respiratory symptom by e-cigarette pack equivalent years by smoking status among Canadian youth (16-25) (n=2660)

# Number of Respiratory Symptoms 1 1.5 2 Ω. 2.3 Pack Equivalent Years .1 0 .4 Never Smokers Ever Smokers .... Daily Smokers Figure

.5

2.5